ArticleGene therapy2005
T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120.
Article in Gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 52 citations in OpenAlex.
- Cellular therapies in rheumatic and musculoskeletal diseases.Journal of translational autoimmunity · 2025Review
- Review
- CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges.Infectious diseases & immunity · 2024Article
- Opportunities for CAR-T Cell Immunotherapy in HIV Cure.Viruses · 2023Review
- Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1.The Journal of clinical investigation · 2021Article
- Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections.Biomedicines · 2021Review
- HIV-1-Specific CAR-T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Enhance Anti-HIV EfficacyFrontiers in microbiology · 2021Article
- CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases.Frontiers in immunology · 2019Review
- Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.Frontiers in immunology · 2019Review
- Chimeric antigen receptor T-cell approaches to HIV cure.Current opinion in HIV and AIDS · 2018Review
- Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.Journal of virology · 2018Article
- Quarter Century of Anti-HIV CAR T Cells.Current HIV/AIDS reports · 2018Review
- Reprint of: Virus-Specific T Cells: Broadening Applicability.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Review
- Virus-Specific T Cells: Broadening Applicability.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Review
- The B-Cell Follicle in HIV Infection: Barrier to a Cure.Frontiers in immunology · 2018Review
- Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir.The Journal of infectious diseases · 2017Review
- Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Combining Cell and Gene Therapy in an Effort to Eradicate HIV.AIDS patient care and STDs · 2016Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-based approaches of cell therapy against viral pathogens such as the human immunodeficiency virus type 1 (HIV-1) could be of primary importance for the control of this viral infection. Here, we designed a chimeric cell surface receptor (105TCR) to provide primary human T-lymphocytes with antibody-type specificity for the HIV-1 envelope glycoprotein. This receptor includes the single chain Fv domain of the neutralizing anti-gp120 human monoclonal antibody F105, CD8alpha hinge and the transmembrane and the cytoplasmic domains of TCRzeta. Our results show that 105TCR is expressed at the cellular surface and is capable of recognizing the HIV-1 envelope glycoprotein inducing highly efficient effector T-cell responses, including extracellular signal-regulated kinase phosphorylation and cytokine secretion. Moreover, human primary CD8+ T-lymphocytes transduced by oncoretroviral and lentiviral vectors containing the 105TCR gene are able to mediate in vitro-specific cytolysis of envelope-expressing cells and HIV-1-infected CD4+ T-lymphocytes. These findings suggest that 105TCR is particularly suited for in vivo efficacy studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.